OncoMatch/Clinical Trials/NCT06515314
HRYZ-T102 TCR-T Cell for AFP Positive Advanced HCC and Other Solid Tumors
Is NCT06515314 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies AFP Specific T Cell Receptor T Cells for hepatic cell carcinoma.
Treatment: AFP Specific T Cell Receptor T Cells — This is a single arm, open-label, dose escalation clinical study to evaluate the safety and efficacy of HRYZ-T102 TCR-T Cell in patients with AFP positive advanced hepatocellular carcinoma and other solid tumors refractory to prior systematic treatments.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Disease stage
Required: Stage BCLC STAGE B, BCLC STAGE C (BCLC)
Barcelona Clinic Liver Cancer (BCLC) stage C or B and Child-Pugh ≤7
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Lab requirements
Blood counts
Leukocytes≥3.0 x 10^9/L; blood platelets ≥75 x 10^9/L; hemoglobin≥85g/L; Absolute lymphocyte count≥0.8 x 10^9/L
Kidney function
Creatinine clearance ≥50mL/min; or serum creatinine ≤1.5×ULN
Liver function
total bilirubin≤3×ULN; ALT/AST≤3×ULN
Cardiac function
LVEF≥50%
Leukocytes≥3.0 x 10^9/L; blood platelets ≥75 x 10^9/L; hemoglobin≥85g/L; Absolute lymphocyte count≥0.8 x 10^9/L Serum albumin ≥ 30g/L; total bilirubin≤3×ULN; ALT/AST≤3×ULN ; Creatinine clearance ≥50mL/min; or serum creatinine ≤1.5×ULN; INR≤1.5×ULN; APTT≤1.5×ULN; LVEF≥50%; SpO2≥92%.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06515314 currently recruiting?
Yes, this trial is currently recruiting patients.
What disease stage is eligible?
Stage BCLC STAGE B or BCLC STAGE C is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify